Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Venlafaxine-Induced Acute Toxic Hepatitis

Venlafaxine에 의한 급성 독성 간염 1예

  • Na, Kyeong-Sae (Department of psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital) ;
  • Hwang, Hee-Sung (Department of psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital) ;
  • Kim, Shin-Gyeom (Department of psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital) ;
  • Lee, So-Young-Irene (Department of psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital) ;
  • Jung, Han-Yong (Department of psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital)
  • 나경세 (순천향대학교 의과대학 부천병원 정신과학교실) ;
  • 황희성 (순천향대학교 의과대학 부천병원 정신과학교실) ;
  • 김신겸 (순천향대학교 의과대학 부천병원 정신과학교실) ;
  • 이소영 (순천향대학교 의과대학 부천병원 정신과학교실) ;
  • 정한용 (순천향대학교 의과대학 부천병원 정신과학교실)
  • Received : 2011.02.28
  • Accepted : 2011.03.28
  • Published : 2011.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Venlafaxine is among the most widely prescribed antidepressants. It is extensively metabolized to O-desmethylvenlafaxine via cytochrome P450 (CYP) 2D6. We report a case of acute toxic hepatitis resulting from venlafaxine in a 54-year-old woman with pain disorder. During venlafaxine treatment, laboratory tests revealed elevated liver enzymes with a maximum of 169 IU/L for aspartate transaminase (AST) and 166 IU/L for alanine transaminase (ALT). AST and ALT levels returned to normal after 6 days of discontinuation of venlafaxine. The patient was finally diagnosed with acute toxic hepatitis through liver biopsy. This case indicates the importance that clinicians should be aware of the hepatotoxicity of venlafaxine in practice.

Keywords

References

  1. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-294. https://doi.org/10.2165/00003495-199549020-00010
  2. Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 1999;19:427-442. https://doi.org/10.1023/A:1006953923305
  3. Courtney DB. Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. Can J Psychiatry 2004;49:557-563. https://doi.org/10.1177/070674370404900807
  4. Rudolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2002:24-30.
  5. Dierick M. A review of the efficacy and tolerability of venlafaxine. Eur Psychiatry 1997;12 Suppl 4:307s-313s. https://doi.org/10.1016/S0924-9338(97)83310-X
  6. Bradley RH, Barkin RL, Jerome J, DeYoung K, Dodge CW. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003;10:318-323. https://doi.org/10.1097/00045391-200309000-00003
  7. Lithner F. Venlafaxine in treatment of severe painful peripheral diabetic neuropathy. Diabetes Care 2000;23:1710-1711. https://doi.org/10.2337/diacare.23.11.1710
  8. Pernia A, Mico JA, Calderon E, Torres LM. Venlafaxine for the treatment of neuropathic pain. J Pain Symptom Manage 2000;19:408-410. https://doi.org/10.1016/S0885-3924(00)00151-2
  9. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998;51:237-254. https://doi.org/10.1016/S0165-0327(98)00222-5
  10. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54S-59S; discussion 59S-61S. https://doi.org/10.1097/00004714-199606002-00011
  11. Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis. Ann Intern Med 2000;132:417.
  12. Horsmans Y, De Clercq M, Sempoux C. Venlafaxine-associated hepatitis. Ann Intern Med 1999;130:944.
  13. Phillips BB, Digmann RR, Beck MG. Hepatitis associated with lowdose venlafaxine for postmenopausal vasomotor symptoms. Ann Pharmacother 2006;40:323-327. https://doi.org/10.1345/aph.1G339
  14. Pradeep RJ, Victor G, Iby N, Kurpad SS, Galgali RB, Srinivasan K. Venlafaxine induced hepatitis. J Assoc Physicians India 2004;52:340.
  15. Sencan I, Sahin I, Ozcetin A. Low-dose venlafaxine-associated liver toxicity in chronic hepatitis. Ann Pharmacother 2004;38:352-353.
  16. Detry O, Delwaide J, De Roover A, Hans MF, Delbouille MH, Monard J, et al. Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report. ransplant Proc 2009;41:3435-3436.
  17. Ostapowicz G, Fontana RJ, SchiOdt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954. https://doi.org/10.7326/0003-4819-137-12-200212170-00007
  18. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003;23:217-226. https://doi.org/10.1055/s-2003-42641
  19. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA 2002;287:2273-2275. https://doi.org/10.1001/jama.287.17.2273
  20. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001;24:483-490. https://doi.org/10.2165/00002018-200124070-00001
  21. Chitturi S, Farrell GC. Herbal hepatotoxicity: an expanding but poorly defined problem. J Gastroenterol Hepatol 2000;15:1093-1099. https://doi.org/10.1046/j.1440-1746.2000.02349.x
  22. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-310. https://doi.org/10.1053/jhep.2001.21083
  23. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-485. https://doi.org/10.1056/NEJMra021844
  24. Andrade RJ, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007;13:329-340. https://doi.org/10.3748/wjg.v13.i3.329
  25. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330. https://doi.org/10.1016/0895-4356(93)90101-6
  26. Kim DJ. The assessment of toxic liver injury. Korean J Gastroenterol 2009;53:5-14.
  27. Sadock BJ, Sadock VA. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 8th ed. Philadelphia: Lippincott Williams & Wilkins;2005. p.2781-2788.
  28. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16:3041-3053. https://doi.org/10.2174/092986709788803097
  29. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000;12 Suppl 1:30-44.
  30. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31:493-502. https://doi.org/10.1111/j.1365-2710.2006.00763.x
  31. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009;29:39-43. https://doi.org/10.1097/JCP.0b013e318192e4c1
  32. Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 2002;17 Suppl 1:S25-S35. https://doi.org/10.1097/00004850-200206001-00004
  33. Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003;73:170-177. https://doi.org/10.1067/mcp.2003.28
  34. Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H, Saxena R, et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010;32:1174-1183. doi: 10.1111/j.1365-2036.2010.04449.x.